Merck & Co., Inc. (MRK) has roughly doubled off its 2025 lows, and investor attention has shifted from "how low can it go" to "how high can it climb." The $180 stock price target stands out because it sits at the upper end of Wall Street's refreshed expectations. Wolfe Research raised its price target to $180, while Morgan Stanley set its objective at $179 and UBS at $175 following Merck's positive Phase 3 results for its personalized melanoma vaccine. A $180 price forecast therefore represents a meaningful but credible milestone—one that would require the stock to break decisively into record territory rather than merely retrace old ground.
Merck is a global pharmaceutical giant headquartered in Rahway, New Jersey, best known for the blockbuster oncology drug Keytruda. Keytruda generated roughly $31 billion in 2025 revenue, close to half of the company's total, alongside a substantial vaccines business led by Gardasil and an animal health segment. The company carries a market capitalization well above $300 billion and offers a dividend yield around 2–3%, making it a fixture in many income and blue-chip portfolios.
The critical structural challenge is the patent cliff: Keytruda's key U.S. patents expire near the end of 2027, opening the door to biosimilar competition in 2028. That looming loss of exclusivity (LOE) has dominated the bear case, keeping the stock's multiple compressed for years even as revenue kept growing.
The bull case rests on Merck's ability to build a credible post-Keytruda growth engine. The August 2026 release of positive Phase 3 data for intismeran autogene, the personalized cancer vaccine developed with Moderna, marked a turning point—shares surged more than 12% on the news. Morgan Stanley cited this readout when it upgraded the stock to Overweight and lifted its target to $179, arguing that Merck's pipeline could fully offset the Keytruda decline and potentially drive additional growth.
Several other catalysts are in the queue. The antibody-drug conjugate (ADC) sac-TMT, in-licensed from Kelun Biotech, is expected to produce an interim readout in the fourth quarter, while tulisokibart, a treatment for inflammatory bowel disease, has updates expected around October. Barclays, BMO Capital, and Argus Research have all raised targets into the $170 range, reflecting growing confidence that these programs can widen Merck's revenue base beyond a single franchise.
The obstacles are equally clear. Keytruda still accounts for roughly half of revenue, and even a successful pipeline transition will not be instantaneous. Analysts expect 2026 earnings to be depressed by significant charges, with a rebound only gradually materializing toward 2027 and 2028 as newer products scale. RBC Capital Markets, which downgraded the stock to Sector Perform while lifting its target to $150, warned that valuation already reflects much of the pipeline optimism and that execution risks may be underestimated.
Valuation is a genuine constraint. After a strong run, the stock trades at a premium to its historical levels, leaving less room for disappointment. If sac-TMT or tulisokibart data fall short of expectations, the market could quickly unwind the premium that recent upgrades have built in.
Wall Street's view has become noticeably more bullish. The consensus rating is a "Buy" or "Moderate Buy," with average price targets clustering in the high $140s to low $150s—but the range is wide. High-end targets now extend to $179 (Morgan Stanley), $180 (Wolfe Research), $175 (UBS), $170 (Argus and BMO), and as high as $186 in some surveys. Goldman Sachs lifted its target to $160. Notably, even the more cautious targets have drifted upward, signaling that the debate has shifted from "can Merck survive the patent cliff" to "how much is the pipeline worth."
From a technical analysis standpoint, the picture is constructive but demanding. The stock's 52-week high sits near $157, meaning $180 is not merely a round psychological number—it requires a sustained breakout to new highs. That zone around $157–$160 is the immediate supply area that must first be converted into support. On the downside, the $140–$145 area represents the first meaningful support level, with a broader base lower in the $125–$130 range. As long as the stock holds above its prior breakout levels, the long-term trend structure favors the upside, but the $180 price target remains a multi-step journey rather than a single catalyst away.
Traders tracking names like Merck can use technology to monitor shifting conditions more efficiently. Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These signals help traders discover new opportunities, keep an eye on existing positions, and identify evolving market trends without manually reviewing every chart. For those following the broader market outlook, integrating AI-generated signals into a disciplined research process can add another layer of perspective.
A move to $180 is ambitious but no longer far-fetched. The strongest support comes from a rapidly maturing pipeline and a series of upgrades from firms willing to look past the Keytruda patent cliff. The primary risk is that valuation has already begun pricing in success, leaving limited margin for error if upcoming readouts disappoint. Investors should monitor the sac-TMT interim data, the tulisokibart update, and any additional detail on how quickly next-generation products can scale revenue. A decisive break above $157–$160 would strengthen the case for $180; a failure to hold the low-to-mid $140s would suggest the market is losing patience with the post-Keytruda story.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.